Advanced Search

 

Study ID Status Title Patient Level Data
SLPT18 Completed A Multi-Centre, Multi-National, Randomised, Double-Blind, Parallel Group Study to Compare the Efficacy and Tolerability of Salmeterol (50mg BID) Administered by Pressurised Inhaler Propelled by a Mixture of Propellants 11 and 12 or by an Alternative Propellant, GR106642X for a Period of…
SM030003 Completed A Single-Centre, Randomised, Placebo-Controlled, Double-Blind, 3-Way Crossover Proof-of-Concept Study to Evaluate the Effect of Reduced Fine Particle Mass (FPM) From the Salmeterol 50mg GR106642X Metered Dose Inhaler Compared With Salmeterol 50mg P11/12 Metered Dose Inhaler on…
SMDT01 Completed A Double-Blind, Double-Dummy, Randomised Crossover Study to Compare the Effect of a Single 50?g Dose of Salmeterol Administered via the Multidose Powder Inhaler (MDPI) or Diskhaler Dry Powder Inhaler With Placebo in Adult Patients With Reversible Airways Obstruction
SMDT02 Completed A Multi-Centre, Randomised, Double-Blind, Double-Dummy, Parallel-Group Study to Determine the Clinical Equivalence of Salmeterol Xinafoate 50mg Twice Daily Delivered via a Multi-dose Powder Inhaler (MDPI) or ROTADISK/DISKHALER in Adolescent and Adult Patients With Reversible Airways Disease
SMK20001 Completed A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group, Dose Response Evaluation of a New Chemical Entity (NCE) and ZYBAN (bupropion hydrochloride) Sustained Release (300mg/day) versus Placebo As Aids to Smoking Cessation.
SMO30006 Completed A Multi-Centre, Randomised, Double-Blind, 12-Week, Parallel-Group Study to Compare Salmeterol Xinafoate 50mcg BD Delivered Either via a HFA Metered-Dose Inhaler or via a CFC Metered-Dose Inhaler, in the Treatment of Adults, Aged 12 years and Over, With Asthma Study Listed on ClinicalStudyDataRequest.com
SMO30007 Completed A Multi-Centre, Randomised, Double-Blind, 12-Week, Parallel-Group Study to Compare Salmeterol Xinafoate 50mcg bd Delivered Either via a HFA Metered-Dose Inhaler or via a CFC Metered-Dose Inhaler, in the Treatment of Children Aged 4-11 Years With Asthma Study Listed on ClinicalStudyDataRequest.com
SMS20010 Completed A Five-Week, Randomized, Double-Blind, Double-Dummy, Two-Period, Four-Treatment Crossover, Placebo-Controlled, Balanced Incomplete Block Design, Multi-Center Study of Salmeterol Xinafoate Inhalation Aerosol, 25mcg BID, 25 mcg TID, 50mcg BID and Placebo Administered…
SMS20011 Completed A Five-Week, Randomized, Double-Blind, Double-Dummy, Two-Period, Four-Treatment Crossover, Placebo-Controlled, Balanced, Incomplete Block Design, Multi-Center Study of Salmeterol Inhalation Aerosol 25mcg BID, 25mcg TID, 50mcg BID and Placebo Administered via a Holding Chamber with Facemask in Subjects with Asthma Aged 6 to 23 Months Study Listed on ClinicalStudyDataRequest.com
SMS30013 Completed A multicentre, randomised, double-blind, crossover study to investigate the efficacy and safety of inhaled salmeterol xinafoate (50?g twice daily from the Diskhaler) compared with placebo (from the Diskhaler) with salbutamol (200?g to use ‘as required’ from the Diskhaler) in children with asthma.
SMS30031 Completed A phase III, multicentre, randomised, double-blind, parallel group study assessing the efficacy and safety of inhaled salmeterol xinafoate 100?g bd via the Diskhaler versus inhaled salbutamol 400?g qds via the Diskhaler in the treatment of patients with moderate to severe asthma.
SMS30032 Completed Comparison of the efficacy, safety and quality of life benefits of inhaled salmeterol (50mcg bd from a Diskhaler) with that of sodium cromoglycate (20mg qds dry powder).
SMS30035 Completed A double-blind, three-way crossover study comparing GR33343G (Salmeterol) 25?g bd, salmeterol 50?g bd and placebo in the treatment of childhood asthma.
SMS30044 Completed A multicentre, randomised, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of salmeterol 50 mg bd administered as a metered-dose inhaler and oral encapsulated ketotifen 1 mg bd in patients with mild to moderate reversible airways obstruction.
SMS30045 Completed A multicentre, double-blind, parallel group, randomised study comparing the efficacy and safety of inhaled salmeterol xinafoate 50 mg bd and beclomethasone dipropionate 500 mg bd with that of salmeterol xinafoate 100 mg bd and beclomethasone dipropionate 500 mg or…
SMS30046 Completed Effects of long-term administration of salmeterol on clinical symptoms, inhaled corticosteroid requirement and bronchial reactivity, and the effect of stopping long-term salmeterol treatment.
SMS30049 Completed A multicentre, double-blind, double-dummy, parallel group, randomised study comparing the efficacy and safety of inhaled salmeterol 50 mg (DISKHALER) administered 12 hourly and oral dose titrated sustained release theophylline administered 12 hourly in patients with reversible airways obstruction.
SMS30059 Completed A double-blind, crossover study comparing the efficacy of 50µg inhaled salmeterol administered twice daily (bd) with 100µg inhaled salmeterol administered once daily at night (nocte) and placebo in subjects with poorly controlled nocturnal asthma.
SMS30073 Completed A multi-centre, double-blind, randomised, parallel group study comparing the addition of inhaled salmeterol with an increase in the dose of inhaled fluticasone propionate in asthmatic patients on a low or intermediate dose of inhaled steroid.
SMS30076 Completed A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Clinical Trial of 4 Weeks Treatment With SEREVENT Inhalation Aerosol, 25mcg BID, 50mcg BID, and Placebo Administered via a Valved Holding Chamber With Facemask in Subjects With Asthma Aged 24 to 47 Months Study Listed on ClinicalStudyDataRequest.com
SMS30077 Completed Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Center Clinical Trial of Four Weeks Treatment with SEREVENT™ Inhalation Aerosol, 25mcg BID, 50mcg BID and Placebo Administered Via a Valved-Holding Chamber with Facemask in Subjects with Symptoms of Asthma or Reactive Airways Disease Age 6 to 23 months Study Listed on ClinicalStudyDataRequest.com
SMS30078 Completed Multicentre, randomised, double-blind, cross-over trial to evaluate the tolerance of Salmeterol protective effect in the asthma of effort.
SMS40003 Completed A randomized, double-blind, double-dummy, parallel group comparison of salmeterol xinafoate inhalation powder (50mcg BID) with oral montelukast (10mg QD) in subjects with persistent asthma symptomatic on concomitant inhaled corticosteroid therapy.
SMS40004 Completed A randomized, double-blind, double-dummy, parallel group comparison of salmeterol xinafoate inhalation powder (50mcg BID) with oral montelukast (10mg QD) in subjects with persistent asthma symptomatic on concomitant inhaled corticosteroid therapy.
SMS40012 Completed Efficacy and safety of Salmeterol in patients with asthma controlled with inhaled corticosteroids

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.